Advertisement

Topics

Immunotec Obtains $2,780,000 of New Financing

20:00 EDT 19 Jul 2015 | Marketwired

VAUDREUIL-DORION, QUEBEC -- (Marketwired) -- 07/20/15 -- Immunotec Inc. (TSX VENTURE: IMM), a direct-to-consumer company and a leader in the nutritional industry (the "Company" or "Immunotec"), announces that it has obtained additional financing from the Toronto Dominion Bank ("TD Bank") and a new credit facility from Export Development Canada ("EDC").

"We are pleased to receive the continued support of TD Bank and partner with EDC for our exportation activities", said Charles L. Orr, Chief Executive Officer of Immunotec. "These additional funds will enable us to continue to invest in our supply chain platform in order to support our activities and growth."

Transaction Highlights

"Immunotec's innovative products have struck an international cord, and EDC's financing is designed to help them take advantage of that increased demand all over the world, not the least of which is their strong upswing in Mexico," said Julie Pottier, Vice-President, Quebec Region, EDC

About Export Development Canada

EDC is Canada's trade finance agency, providing financing and insurance solutions locally and around the world to help Canadian companies of any size respond to international business opportunities. As a profitable Crown corporation that operates on commercial principles, EDC works together with private- and public-sector financial institutions to create greater capacity for Canadian companies to engage in trade and investment.

About Immunotec Inc.

Immunotec is a Canadian-based Company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S. and Mexico. The Company offers an extensive family of nutritional products targeting health, wellness, weight management, as well as energy and performance. The Immunocal family of products is supported by over 40 published articles and supporting science in medical and scientific literature.

Please visit us at www.immunotec.com for additional information.

The Company files its continuous disclosure documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Patrick Montpetit CPA,CA, CF Vice-President and Chief Financial Officer Immunotec Inc. (450) 510-4527 NEXT ARTICLE

More From BioPortfolio on "Immunotec Obtains $2,780,000 of New Financing "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Endocrinology
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...